PPIDT00392
Drug Information
| Name | Lanadelumab |
|---|---|
| Sequence | EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG |
| DrugBank_ID | DB14597 |
| Type | biotech |
| Indication | Lanadelumab is indicated for prophylaxis to prevent attacks in adult and pediatric patients aged 2 years and older with hereditary angioedema.[L45108,L49221] In Canada, it is indicated for use only in adults and adolescents.[L49226] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
300 MG
|
| Injection, solution | Subcutaneous |
150 mg
|
| Injection, solution | Subcutaneous |
300 mg
|
| Injection, solution | Subcutaneous |
300 mg/2mL
|
| Solution | Subcutaneous |
150 mg/1mL
|
| Solution | Subcutaneous |
300 mg/2mL
|
| Solution | Subcutaneous |
300 mg / 2 mL
|
| Injection, solution | — |
300 mg/2ml
|